Inventor · disambiguated record
Niranjan B. Pandey
Also filed as: PANDEY NIRANJAN · PANDEY NIRANJAN B · PANDEY NIRANJAN BABU
14 granted patents·11 pending applications·34 citations·filing 2005–2024
89Inventor score
Files withUNIV JOHNS HOPKINS10JANSSEN PHARMACEUTICA NV4PATERSON BLAKE3ALBA THERAPEUTICS CORP2ASCLEPIX THERAPEUTICS LLC2
Top patents by PatentIndex Score
25 records- 0191US8299017B2Use of tight junction antagonists to treat inflammatory bowl diseasePATERSON BLAKE·Filed 2010·Granted Oct 30, 2012·8 cites·14 claims
- 0290US8796203B2Use of tight junction antagonists to treat inflammatory bowel diseasePATERSON BLAKE·Filed 2012·Granted Aug 5, 2014·6 cites·14 claims
- 0384US11981754B2Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseasesUNIV JOHNS HOPKINS·Filed 2020·Granted May 14, 2024·1 cites·29 claims
- 0483US9056923B2Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphagiogenesis-dependent diseasesPOPEL ALEKSANDER S·Filed 2011·Granted Jun 16, 2015·3 cites·5 claims
- 0583US7579356B2Thia-tetraazaacenaphthylene kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Aug 25, 2009·9 cites·27 claims
- 0680US10774112B2Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseasesUNIV JOHNS HOPKINS·Filed 2017·Granted Sep 15, 2020·1 cites·21 claims
- 0780US2024391957A1Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseasesUNIV JOHNS HOPKINS·Filed 2024·Application pending·0 cites
- 0878US9802984B2Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseasesUNIV JOHNS HOPKINS·Filed 2014·Granted Oct 31, 2017·3 cites·51 claims
- 0976US10106597B2Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis-dependent diseasesUNIV JOHNS HOPKINS·Filed 2016·Granted Oct 23, 2018·1 cites·17 claims
- 1072US11155603B2Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis- dependent diseasesUNIV JOHNS HOPKINS·Filed 2020·Granted Oct 26, 2021·0 cites·11 claims
- 1171US7605154B2Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2006·Granted Oct 20, 2009·2 cites·5 claims
- 1271US2009069247A1Use of tight junction antagonists to treat inflammatory bowel diseasePATERSON BLAKE·Filed 2007·Application pending·0 cites
- 1370US2014296165A1Use of tight junction antagonists to treat inflammatory bowel diseaseALBA THERAPEUTICS CORP·Filed 2014·Application pending·0 cites
- 1466US10774131B2Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis-dependent diseasesUNIV JOHNS HOPKINS·Filed 2018·Granted Sep 15, 2020·0 cites·18 claims
- 1562US2016151449A1Use of tight junction antagonists to treat inflammatory bowel diseaseALBA THERAPEUTICS CORP·Filed 2016·Application pending·0 cites
- 1660US7427625B2Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2007·Granted Sep 23, 2008·0 cites·19 claims
- 1760US2008300264A1Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitorsCONNOLLY PETER J·Filed 2008·Application pending·0 cites
- 1856US2015307592A1Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseasesUNIV JOHNS HOPKINS·Filed 2015·Application pending·0 cites
- 1952US2024226241A1Formulations for intraocular delivery of peptides derived from type iv collagenASCLEPIX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2045US2020179285A1Biodegradable microparticles for sustained delivery of anti-angiogenic peptideUNIV JOHNS HOPKINS·Filed 2018·Application pending·0 cites
- 2143US2008108611A1Substituted thienopyrimidine kinase inhibitorsBATTISTA KATHLEEN A·Filed 2007·Application pending·0 cites
- 2242US7659284B2Thiazolopyridine kinase inhibitorsJANSSEN PHARMACEUTICA NV·Filed 2005·Granted Feb 9, 2010·0 cites·13 claims
- 2340US11674959B2Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptorsUNIV JOHNS HOPKINS·Filed 2018·Granted Jun 13, 2023·0 cites·15 claims
- 2439US2019225670A1Compounds and methods for activating tie2 signalingASCLEPIX THERAPEUTICS LLC·Filed 2017·Application pending·0 cites
- 2538US2018339024A1Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulationsASCLEPIX THERAPEUTICS LLC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →